"Azacitidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
| Descriptor ID |
D001374
|
| MeSH Number(s) |
D02.145.150 D03.383.742.680.245.217 D13.570.685.245.217 D13.570.800.286.300
|
| Concept/Terms |
Azacitidine- Azacitidine
- 5-Azacytidine
- 5 Azacytidine
- Azacytidine
|
Below are MeSH descriptors whose meaning is more general than "Azacitidine".
Below are MeSH descriptors whose meaning is more specific than "Azacitidine".
This graph shows the total number of publications written about "Azacitidine" by people in this website by year, and whether "Azacitidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 5 | 0 | 5 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 4 | 3 | 7 |
| 2007 | 3 | 0 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2013 | 3 | 2 | 5 |
| 2014 | 3 | 5 | 8 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 1 | 4 |
| 2017 | 5 | 1 | 6 |
| 2018 | 1 | 4 | 5 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 3 | 5 | 8 |
| 2024 | 4 | 1 | 5 |
| 2025 | 3 | 0 | 3 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azacitidine" by people in Profiles.
-
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. J Clin Oncol. 2026 Sep 10; 44(26):2529-2542.
-
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025 11; 39(11):2697-2707.
-
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025 Jul 31; 146(5):590-600.
-
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
-
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 11 26; 8(22):5735-5743.
-
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 04 23; 8(8):2020-2029.
-
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 04; 99(4):615-624.
-
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440.
-
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904.